Eli Lilly Reports the Availability of Verzenio (abemaciclib) for Metastatic Breast Cancer in Canada

 Eli Lilly Reports the Availability of Verzenio (abemaciclib) for Metastatic Breast Cancer in Canada

Shots:

  • The approval of Verzenio is based on results of two P-III and one P-II study. The P-III MONARCH 3 study assessing Verzenio + anastrozole/letrozole vs PBO in 493 postmenopausal women in a ratio (1:1) with HR+, HER2- advanced BC prior not treated with systemic therapy
  • The P-III MONARCH 2 involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 patients in ratio 1:1 with HR+, HER2- mBC who progressed on endocrine therapy. The P-II MONARCH-1 study result assessing Verzenio (200 mg) in 132 patients with HR+, HER2- mBC resulted in 19.7% ORR, 8.6 mos. DoR
  • Verzenio (abemaciclib) is CDK 4 & 6 inhibitor activated by binding to D-cyclins with 150mg as recommended dose in combination therapy and 200mg in monothx. Verzenio is available in four tablet strengths (200 mg, 150 mg, 100 mg, and 50 mg)

Click here to­ read full press release/ article | Ref: PR Newswire | Image: The Street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post